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ABSTRACT 
Background: Previous research has suggested that sodium citrate improves hyposmia by decreasing 
mucus calcium levels in the nose. This study aimed to confirm or refute this effect in a single 
application and assess potential side effects.  
Methodology: Study design was a randomised double-blind controlled trial of sodium citrate nasal 
spray (intervention) versus sterile water (control) in a tertiary care clinic. Fifty-five patients with non-
conductive olfactory loss were randomised to receive the intervention or placebo. The primary 
outcome measure was improvement in measured olfactory thresholds for phenyl ethyl alcohol (PEA) 
over 2 hours. Other outcome measures assessed were Improvement in olfactory thresholds in 1-
butanol, eucalyptol and acetic acid; number of responders with a clinically relevant response in each 
arm; adverse effects.   
Results: A significant effect was seen in the intervention arm for PEA and for 1-butanol and 
eucalyptol when compared to the control arm (P<0.05); 32% of the intervention arm responded in 
terms of improved sensitivity towards some of the odours. Minor adverse effects noted included 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
sore throat, nasal paraesthesia, slight rhinorrhoea and itching. The duration of effect of the citrate is 
transient, peaking at 30-60 minutes after application. 
Conclusions: Sodium citrate yields some potential as a treatment for non-conductive olfactory loss, 
however these findings require corroboration in further clinical trials looking at longer-term regular 
use of the spray as a viable therapeutic option for patients where it would be applied at frequent 
intervals such as before meal times. 
 
Keywords: olfaction disorders, clinical trial, smell, sodium citrate, viral respiratory tract infections 
 
INTRODUCTION 
Background 
   Olfactory disturbances represent a frustration for both patients and otorhinolaryngologists; the 
effects may be profound for some patients especially if their profession or safety depends upon it 
and clinicians often feel unable to do much more than identify the problem. Disorders of olfaction 
have a widespread heterogeneous aetiology from nasal to central causes. They lead to a significant 
impact on nutritional intake, are frequently associated with weight loss, decreased social pleasure, 
diminished interpersonal relationships and poor psychological well-being 1. Olfactory disorders 
increase in incidence with age and may be as common as 1 in 5 in the over 65 population2, 3. 
Underlying the challenge of management has been a lack of understanding of the olfactory system 
and a lack of therapeutic options available to clinicians. 
 
  The current understanding of olfactory transduction suggests that olfactory receptor cells in the 
olfactory cleft bind odour molecules to a large family of receptors in the ciliary membrane. These 
subsequently activate a G protein-coupled intracellular cascade ending with synthesis of cAMP by 
adenylyl cyclase. The rise in intracellular cAMP leads to the opening of cyclic nucleotide-gated 
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channels and an influx of Na+ and Ca2+, which eventually may lead to axonal firing. Calcium plays a 
key, conflicting, role in the responses of the olfactory receptor cells. It acts both as an excitatory 
second messenger to increase the magnitude of receptor current but also as an inhibitory 
messenger important in response termination and adaptation. It is well established that cytoplasmic 
Ca2+ regulates sensitivity to cAMP4, 5. By entering the cilium during the odorant response Ca2+ 
reduces the sensitivity of cyclic nucleotide gated (CNG) channels to cAMP6.   
   A rise in mucosal Ca2+ through the above-described mechanism increases negative feedback on the 
olfactory pathway ultimately reducing sensitivity to odorant stimulus. In the normosmic patient this 
provides a mechanism for long-term odour adaptation. It is therefore possible that in the patients 
with olfactory loss, reducing mucosal Ca2+ levels may reduce the negative feedback, which in these 
circumstances may contribute to their anosmia/hyposmia. This effect is supported by an animal 
study that found prolonged olfactory stimulation in frog olfactory receptor cells when creating a 
similar environment5, 7.  Modulation of calcium concentrations in the olfactory environment would 
therefore certainly be an attractive target for pharmacologic intervention in humans, with an 
established underlying physiological basis. 
   Sodium citrate, a solution licenced and used safely in other body cavities (e.g. stomach and 
bladder) is known to buffer calcium ions, leading to a reduction in mucosal Ca2+ and subsequent 
reduction in negative feedback. A previous study by Panagiotopoulos et al has suggested that the 
application of sodium citrate improves hyposmia by decreasing mucus calcium levels in the nose 8.  
On the basis of the above physiological rationale, reduction in free Ca2+ ions is likely to increase the 
excitability of olfactory neurons, thus improving the sense of smell.  The sodium citrate solution 
douched in the nose should have the effect of binding free calcium ions in the nasal mucus, thus 
reducing mucosal calcium. The Panagiotopoulos study did, however, have certain limitations 
including the small number of participants and the method of application as well as the use of an 
identification test as the main assessment of olfactory performance. 
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Objectives 
Primary objective: To measure the effect of sodium citrate nasal spray on short-term olfactory 
performance compared to placebo.    
Secondary objectives: To determine the acceptability of sodium citrate nasal spray as a treatment 
for olfactory disorders.  
 
MATERIALS AND METHODS 
Ethical approval and funding 
Ethical approval was sought and obtained from the Eastern Multicentre Research Ethics committee 
(REC reference number 06/MRE05/16) in accordance with the provisions of the Declaration of 
Helsinki and Good Clinical Practice guidelines. Sodium citrate solution and corresponding sterile 
water placebo were supplied by the James Paget University Hospital pharmacy. The study was 
funded by the James Paget University Hospital Research & Development Department and sponsored 
by the University Hospitals of Leicester NHS Trust. 
 
Trial Design 
The study was conducted as a randomised double-blind controlled trial recruiting 55 patients who 
met criteria below. 
Participants 
Patients referred to a tertiary Smell & Taste Disorders clinic were assessed for eligibility and 
approached by the lead author. Basic demographic data including age and sex were collected.   
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Inclusion criteria: 
• All patients with non-conductive olfactory disorders (NCODs) as confirmed by history and 
examination 
•  
Exclusion criteria:  
• Patients with any endoscopic findings of conductive loss including chronic rhinosinusitis 
with/without nasal polyposis and severe nasal septal deviation (preventing passage of 4mm 
endoscope) 
• Patients with congenital anosmia 
• Patients with any inhalant allergies 
• Patients with asthma 
• Children under the age of 16  
All patients provided written informed consent after the aims and methods of the study had been 
described to them and after they had received an information sheet.  
 
Interventions 
Participants were randomly allocated to one of two groups. In the treatment arm, participants were 
sprayed with 1ml of 9% sodium citrate solution; 0.5ml to each side of the nose. Participants in the 
control arm received the corresponding volume of sterile water. The solution was applied using a 
nozzle adapted to target the olfactory cleft (figure 1) as can be found on other nasal spray kits such 
as co-phenylcaine; the nozzle was manipulated to point upwards prior to insertion into the nose. 
Sodium citrate concentrations used did not exceed those used in other body cavities. Sterile water 
was chosen as the control agent as the ionic composition of saline may have a local effect on the Na+ 
ion concentrations that we hypothesised might modulate olfaction. 
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Outcomes 
Primary outcome measure:  
Best improvement in olfactory thresholds compared to baseline as defined by threshold shift in 
logarithmic dilutions in the direction of the weaker odour concentration for PEA odour. 
 
Secondary outcome measures:  
• Best improvement in olfactory threshold compared to baseline for all odours as defined by a 
threshold shift of at least more than one in the direction of the weaker odour concentration. 
• Number of individuals who responded; (for those individuals who responded we also recorded 
the time until best improvement)  
• Adverse events 
Subjects underwent a series of threshold smell tests using the phenyl ethyl alcohol (roses), 1-butanol 
(pear), acetic acid (vinegar) and eucalyptol (menthol) on the basis of previous work by the senior 
authors9 and in conjunction with accepted threshold testing formats previously validated10, 11.  A 
50ml volume of each of 4 odours in 250ml bottles were arranged in seven 10-fold dilutions from 10-1 
to 10-7 for 1-Butanol, Acetic acid and Eucalyptol and 10-2 to 10-8 for phenyl alcohol. At the beginning 
of the trial the odour mercaptan was used but was subsequently replaced with 1-Butanol due to the 
need to replenish the odour solutions more frequently than the others and was deemed an 
unreliable test odour.  
The format of the test had been fully explained to the subject beforehand by the research nurse who 
tested the patient. This format of olfactory testing was chosen as it would allow for quicker 
reassessment at repeat intervals compared to a full Sniffin’ Sticks test battery, but would provide a 
more accurate assessment of olfactory performance than an identification only test 12. The subject 
was then started with the smallest concentration of each odour and with sterile water for 
comparison, ascended through the odour concentrations in a forced response format until they 
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correctly detected the odour as distinct from the sterile water 10. Once the subject had correctly 
identified two concentrations of a single odour in a row, the weaker concentration of the odour 
detected was taken as their threshold and recorded. This was then repeated for the remaining 3 
odours and the four thresholds obtained were considered the baseline olfactory performance. The 
format of the test had been fully explained to the subject beforehand by the research nurse who 
tested the patient 10, 12. 
 
After application of the intervention, the olfactory threshold tests to the four odours were then 
repeated every fifteen minutes up to a maximum of 120 minutes. At each 15-minute interval, 
patients were started two places below their previous threshold to avoid unnecessary extra steps. 
The maximum change in threshold was recorded for each odour, as was the duration of any effect if 
seen. If no improvement was noted for all four odours by 60 minutes then further testing was 
abandoned. 
At the end of the trial participants were asked to report any adverse effects from the spray they had 
received. 
 
Sample size 
To detect a moderate to large Cohen's effect size of 0.75 (mean difference /standard deviation of 
the difference), at 80% power at the 5% level of significance, would need 30 patients in each arm.  
 
Randomisation 
Sequence generation, allocation concealment and implementation: 
The code randomisation sequence was computer generated and coded bottles of solution were 
provided to researchers who had no knowledge of the contents of each bottle.  The random 
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sequence was generated by Microsoft Excel number randomiser generator in the hospital pharmacy 
who assigned enrolled participants to the intervention. Once the participant agreed to be in the 
study the study nurse phoned the pharmacy who then provided a coded bottle to use in the clinic. 
Blinding: 
Both the research team and the participants were blinded to the intervention. At the end of the trial 
the bottle code was obtained from the pharmacy and revealed showing allocation of participants to 
the two groups.  
 
Statistical methods: 
The analysis included all randomised individuals who had valid outcome measurements. The primary 
analysis compared the best improvement with the PEA odour between control and intervention 
groups using a Mann-Whitney test as the outcome was not normally distributed. The same analysis 
was also performed separately for each odour tested for the best improvement and the duration. 
Response to treatment, defined by a difference of at least two thresholds, was tested using a chi-
squared test. We considered p<=0.05 as significant and all statistical analyses were conducted using 
Stata 14.0/SE.     
 
RESULTS 
Participant flow: 
A total of 98 patients were assessed for eligibility and after exclusion or declining, 61 participants 
were randomised, with 31 allocated to the treatment arm and 30 to the control arm, but 4 
participants did not attend their appointment on the day and 2 didn’t complete the sequence of 
testing after application (see figure 2). The trial ran from October 2007 to December 2014 and 
stopped when the target sample size had been recruited. 
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Baseline data: 
Female participants accounted for 76% of those in the trial with an age range of 20 to 79 (mean of 
53) in all subjects. The underlying diagnoses were post-viral olfactory loss (26, 42%), post-traumatic 
olfactory loss (9, 16%) and idiopathic (20, 36%). On psychophysical olfactory testing (using the 
Sniffin’ Sticks), 29 (52%) were functionally anosmic and 17 (30%) were hyposmic; the TDI score was 
irretrievable for 2 subjects and not performed in 7 subjects. The balance of the two treatment arms 
is shown in table 1, it can be seen that there is some difference between the groups in terms of 
gender and diagnosis.  
 
Numbers analysed: 
As participation in the trial only required one visit and one intervention, all participants completed 
the trial once randomised except for four in the control arm who failed to attend the study visit and 
a further two that failed to complete the sequence of tests on the study visit.  Due to the small 
number of participants that had been tested with mercaptan (7), no specific analysis of this data was 
undertaken. 
Outcomes and estimation: 
Based on a best improvement in thresholds (logarithmic concentration being lower than baseline), 
there were significant differences between the intervention and control groups (p<0.05) for all 
odours except for ACA (Table 2a). Based on a clinically significant shift in thresholds of 2 or more, 10 
participants responded to PEA, 10 to 1-BUT, 9 to ACA and 9 to EUC; again these were clinically 
significant for 1-BUT and EUC and approaching significance for PEA (table 2b). In seven patients who 
were evaluated with mercaptan instead of 1-butanol, 4 hyposmic patients (out of the 7) showed a 
positive threshold shift of ≥2 places in response to citrate. Table 3 shows the proportions of anosmic 
and hyposmic patients demonstrating that baseline olfactory performance does not necessarily 
appear to be a reliable indicator of potential to respond to the intervention.  
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Ancillary analyses 
Of the 10 intervention subjects (32%) who found an improvement for at least one odour, 5 of the 10 
had improved at 15 minutes with 3 reaching peak improvement at 15 minutes. For the other 7, peak 
improvement was reached at 30 minutes for five subjects, 45 minutes for one and 60 minutes for a 
another one (two examples are provided in figure 3). The average time for subjects to register 2 
logarithmic dilution improvements in threshold was 38.7 minutes with the average time to 
maximum effect 47.4 minutes and the average duration 54 minutes. In most patients the threshold 
levels for all odours had returned to baseline (+/- 1 threshold step) by the end of the 2-hour test 
period. Fourteen patients did not continue repeat threshold testing beyond 60 minutes due to a lack 
of response following the intervention. 
 
Harms: 
None of the participants in the trial reported any persistent symptoms but transient localised 
symptoms were reported in both arms with rhinorrhoea and sore throat affecting only the citrate 
recipients (Table 4). None were reported as excessively unpleasant. 
 
DISCUSSION 
Generalisability 
   These results mark a promising development in the treatment of NCODs disorders. We have shown 
that sodium citrate nasal spray may temporarily improve the ability to detect certain odours in those 
quantitative olfactory disorders. Sodium citrate therefore has the potential to be a treatment or 
adjunct to treatment to improve the olfactory performance of those with NCODs. We have shown 
that sodium citrate spray appears to be relatively quick acting in those who find improvement, is 
acceptable to patients, and could feasibly be used in a clinical setting. The current treatment 
armoury for this condition is limited with oral and topical corticosteroid and methylxanthine class 
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drugs (e.g. Theophylline 13) showing the most promise to date. Of these the only level I evidence is 
for prednisolone 14, 15 in NCODs. The topical intranasal spray allows an easy and well-tolerated mode 
of application that is vital when considering its development as a therapeutic solution. It may 
facilitate short-term olfactory enhancement allowing patients greater enjoyment of meals, 
improving quality of life and nutritional intake, or it may be used as a regular application to allow 
better baseline olfactory function; the specific nature of the improvement cannot be elucidated 
from these results, although the quick time to improvement is encouraging since it would make 
timing of use of the spray practicable. It is notable that amongst those who responded, the effect 
was not universal across all 4 odours. 
Limitations 
Whilst a positive effect was seen in 10 participants in the intervention arm, there remained 21 
participants who perceived no discernible effect on their olfactory performance and therefore this 
cannot be seen as a panacea for all patients with NCODs. The sample size here is too small to allow 
for a subgroup analysis by diagnosis, however, there does not appear to have been a specific 
clustering of responders within one subgroup (PVOL), suggesting that more than one group may 
stand to benefit from this intervention (table 5). Therefore although the diagnostic group with the 
greatest number of responders is the PVOL group, it is notable that patients in the idiopathic group 
also responded. It is however possible that the idiopathic cases are indeed post-viral in nature even 
if lacking in the temporal relation to an upper respiratory tract infection. It should also be noted that 
the different subgroups may well reflect different sites of pathology within the olfactory apparatus 
(i.e. olfactory epithelium/receptors in PVOL, olfactory nerves/secondary cortex in PTOL, etc), so 
future studies will need to power for individual subgroups. Seven participants were tested with 
mercaptan rather than 1-butanol but and so this data was not used in the analysis, but we do not 
believe this detracts from the findings presented here. 
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The trial as reported here is designed to assess the use of sodium citrate in a single application for 
NCODs. However, to be effective as a treatment for patients, this positive effect would need to be 
repeatable on subsequent applications and to be tolerated by patients. In practice, due to the short 
duration of effect, this would involve patients having to apply the spray to their noses at frequent 
intervals such as meal times, however, feedback from patient panels at our institution favour this 
possibility. Other concentrations of sodium citrate could have been considered, however we decided 
to select the highest concentration currently available to reduce the sample size needed for this trial. 
As our primary outcome we used was olfactory threshold tests that only assessed 4 odours, it is 
possible that testing a wider array of odours might have enabled more positive responses, albeit that 
practically speaking this would have been difficult to achieve with 15-minute intervals for threshold 
tests, but achievable with an identification test. 
Interpretation 
   The data presented here do not thrust sodium citrate spray forwards as a therapeutic option 
immediately, but do suggest merit in undertaking further multicentre trials to evaluate this 
intervention further. Seen in conjunction with the previous trial 8 of sodium citrate in olfactory 
disorders, the results do not appear to be spurious. In fact a recent trial at the Dresden Smell & Taste 
Clinic performed using one nostril as the test site and the contralateral one as a control has shown 
benefit in the PVOL diagnostic group too16. A subsequent trial would need to address the issue of 
subgroup analysis by diagnosis as well as age, gender and degree of olfactory impairment with an 
appropriate sample size.  As this trial evaluated a single application of sodium citrate spray, further 
work needs to consider the benefits or otherwise of repeated use of the treatment over the short to 
medium term. Comparing efficacy between pH and sodium matched controls using validated 
olfactory outcome measures would also test our hypothesis that it is the citrate and our postulated 
mechanism of action that is conferring the improvement, rather than adjustment of any other 
intracellular signalling pathway or enhancement of the enzymatic mediators of olfaction through 
optimisation of their acid-base environment.  
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CONCLUSION 
This work offers proof of concept that sodium citrate nasal spray may enhance olfaction in some 
patients with NCODs. Further investigation through well-designed clinical trials may deliver better 
evidence to suggest that it has a place in the rhinologist’s armamentarium. If further proven to 
enhance olfaction, sodium citrate could safely and easily be formulated into a commercial applicator 
to allow temporary relief of smell loss. This may serve to enhance the quality of life of such patients 
with few side effects or contraindications, by providing relief for meal times for example. 
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TABLES 
Table 1: Demographic and baseline information 
 Control (n= 24) Intervention (n= 31) 
 Mean (SD) Mean (SD) 
Female n (%) 16 (66.7) 26 (83.9) 
Age (years) 52.5 (10.4) 54.1 (14.3) 
Threshold score  2.0 (1.7) 2.4 (2.5) 
Discrimination score 6.5 (3.4) 6.8 (2.7) 
Identification score 7.7 (3.5) 5.6 (2.5) 
TDI score * 16.2 (7.3) 14.8 (5.9) 
Diagnosis n (%)  
  IDIOPATHIC 7 (29.2) 13 (41.9) 
  PTOL 5 (20.8) 4 (12.9) 
  PVOL 12 (50.0) 14 (45.2) 
Classification (Based on TDI)  
   Functional anosmia 13 (61.9) 16 (64.0) 
  Hyposmia 8 (38.1) 9 (36.0) 
* Not available in 9 subjects 
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Table 2a: Best improvement measured in number of threshold levels improved 
Odour tested Control (n= 24) Intervention (n= 31)
Median (IQR) Median (IQR) p-value
PEA  0 (0-0.5) 1 (0-2) 0.0139
BUT 0 (0-1) 1 (0-2) 0.0111
ACA 0 (0-1.5) 1 (0-2) 0.2827
EUC 0 (0-0) 1 (0-2) 0.0001
 
Table 2b: Number of respondents  
Odour tested Control (n= 24) Intervention (n= 31)
Median (IQR) Median (IQR) p-value
PEA  3 (12.5) 10 (32.3) 0.087
BUT 3 (12.5) 14 (45.2) 0.009
ACA 6 (25.0) 9 (29.0) 0.739
EUC 1 (4.2) 9 (29.0) 0.018
 
Table 3: Number of responders to citrate by baseline olfactory performance in the intervention 
arm 
Responders by odour Functionally anosmic Hyposmic Total 
PEA 3 7 10 
BUT 4 6 10* 
ACA 6 3 9 
EUC 6 3 9 
* 4 unclassified as did not have a TDI score 
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Table 4: Side-effects of the intranasal spray 
Side effect Citrate Control
Nasal irritation 7 4
Rhinorrhoea 11 0
Nasal congestion 3 1
Sneezing 2 0
Sore throat 12 0
Dysgeusia 1 1 
 
 
Table 5: Numbers of responders to citrate by diagnostic group in the intervention arm 
Responders by odour PVOL PTOL Idiopathic 
PEA 6 1 3 
BUT 6 1 3 
ACA 5 1 3 
EUC 4 1 4 
 
FIGURE LEGENDS 
Figure 1: Spray bottle and nozzle 
Figure 2: Citrate RCT participant flow chart 
Figure 3 and 4: Time and duration of effect in two example responders by odour 
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